Eculizumab

Drug Profile

Eculizumab

Alternative Names: 5G1-1; 5G1.1; Anti-C5 monoclonal antibody 5G1-1; h5G1.1; Monoclonal antibody 5G1-1; Soliris

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator Alexion Pharmaceuticals
  • Developer Alexion Pharmaceuticals; Brigham and Womens Hospital; Chiba University
  • Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Delayed graft function; Neuromyelitis optica; Transplant rejection; Haemolytic uraemic syndrome; Myasthenia gravis; Dermatomyositis; Membranous glomerulonephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
  • Preregistration Myasthenia gravis
  • Phase III Delayed graft function; Neuromyelitis optica
  • Phase II Guillain-Barre syndrome; Renal transplant rejection
  • Preclinical Heart transplant rejection
  • No development reported Antiphospholipid syndrome
  • Discontinued Adult respiratory distress syndrome; Age-related macular degeneration; Allergic asthma; Autoimmune haemolytic anaemia; Bullous pemphigoid; Dermatomyositis; Glomerulonephritis; Immune thrombocytopenic purpura; Lupus nephritis; Membranous glomerulonephritis; Motor neuron disease; Psoriasis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 09 Jan 2017 Preregistration for Myasthenia gravis in European Union and USA (IV)
  • 21 Dec 2016 Efficacy and adverse events data from a phase II/III trial in Delayed graft function (Prevention) released by Alexion
  • 27 Oct 2016 Alexion announces intention to submit regulatory submissions for myasthenia gravis to USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top